Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.43 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454163 | 0.98 | CNR2 (0.52) | CNR2SIGMAR1APEX1CNR1PDE10A | |
| SCHEMBL5449136 | 0.92 | PDE10A (0.52) | CNR2APEX1PDE10APOLBGAA | |
| SCHEMBL5463426 | 0.92 | CNR2 (0.45) | CNR2SIGMAR1APEX1CNR1PDE10A | |
| SCHEMBL14411440 | 0.91 | CNR2 (0.47) | CNR2APEX1CNR1PDE10AFPR3 | |
| SCHEMBL14412051 | 0.90 | CNR2 (0.47) | CNR2APEX1CNR1PDE10AFPR3 | |
| SCHEMBL5448906 | 0.90 | CNR2 (0.48) | CNR2APEX1CNR1PDE10AFPR3 | |
| SCHEMBL5454797 | 0.90 | CNR2 (0.50) | CNR2PDE10ASMYD2POLBGAA | |
| SCHEMBL5448901 | 0.90 | PDE10A (0.53) | CNR2PDE10APOLBGAA | |
| SCHEMBL5459780 | 0.89 | CNR2 (0.46) | CNR2SIGMAR1APEX1CNR1PDE10A | |
| SCHEMBL5446718 | 0.89 | CNR1 (0.47) | CNR2SIGMAR1APEX1CNR1SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007079239-A2 | BICYCLIC NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CNR2 106/4885SIGMAR1 175/4885APEX1 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.